Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
T Vu, H Wiendl, M Katsuno, SW Reddel… - Neuropsychiatric …, 2023 - Taylor & Francis
The terminal complement C5 inhibitor ravulizumab was engineered from the humanized
monoclonal antibody eculizumab to have an extended half-life and duration of action. It …
monoclonal antibody eculizumab to have an extended half-life and duration of action. It …